We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12
News

NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12

NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12
News

NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NOXXON Pharma AG has announced that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF) under the ministry’s small and medium enterprise innovation initiative (KMU-Innovativ).

The grant was presented to NOXXON following the completion of a peer reviewed selection process. Under the initiative NOXXON will receive 1.2 million Euro (1.7 million US$) in funding for the impending phase I clinical development of its candidate Spiegelmer® NOX-A12.

The company develops NOX-A12 for use in autologous hematopoietic stem cell transplantation in patients suffering from non-Hodgkin’s lymphoma or multiple myeloma.

NOXXON’s Chief Executive Officer Frank Morich commented: “In awarding this competitive research grant to NOXXON, the BMBF acknowledges our tremendous progress in maturing Spiegelmer® compounds into therapeutic candidates for human use. The transition from pre-clinical studies to clinical trials is a critical junction in the development of an innovative compound. We are grateful to the BMBF for providing grant support at this crucial stage.”

Spiegelmers® (L-aptamers) are chemical entities based on synthetic mirror-image oligonucleotides. Due to their unique mirror image configuration Spiegelmers® are not metabolized and do not hybridize with native nucleic acids. Spiegelmers® also do not activate the innate immune response via Toll-like receptors and have shown an exceptionally favorable immunogenicity profile in pre-clinical testing.

The phase I clinical development of NOX-A12 will follow closely behind that of NOXXON’s lead candidate NOX-E36, which entered human testing in June of 2009.
Advertisement